keyword
MENU ▼
Read by QxMD icon Read
search

managment tnbc

keyword
https://www.readbyqxmd.com/read/28544579/frizzled7-antibody-functionalized-nanoshells-enable-multivalent-binding-for-wnt-signaling-inhibition-in-triple-negative-breast-cancer-cells
#1
Rachel S Riley, Emily S Day
Antibodies that antagonize cell signaling pathways specific to their targeted receptor are invaluable tools to study and treat malignancies, but their utility is limited by high production costs and treatment dosages. Researchers have shown that antibodies conjugated to nanoparticles display increased affinity for their target relative to freely delivered antibodies due to multivalency, and this study investigates how this multivalency can enable antibody-nanoparticle conjugates to inhibit oncogenic cell signaling more effectively than freely delivered antibodies...
May 22, 2017: Small
https://www.readbyqxmd.com/read/28461119/taraxacum-mongolicum-extract-induced-endoplasmic-reticulum-stress-associated-apoptosis-in-triple-negative-breast-cancer-cells
#2
Xiao-Hong Li, Xi-Ran He, Yan-Yan Zhou, Hai-Yu Zhao, Wen-Xian Zheng, Shan-Tong Jiang, Qun Zhou, Ping-Ping Li, Shu-Yan Han
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive and deadly breast cancer subtype with limited treatment options. It is necessary to seek complementary strategies for TNBC management. Taraxacum mongolicum, commonly named as dandelion, is a herb medicine with anti-cancer activity and has been utilized to treat mammary abscess, hyperplasia of mammary glands from ancient time in China, but the scientific evidence and action mechanisms still need to be studied. AIM OF THE STUDY: This study was intended to investigate the therapeutic effect and molecular mechanisms of dandelion extract in TNBC cell line...
April 28, 2017: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/28410132/tackling-intra-and-inter-tumor-heterogeneity-to-combat-triple-negative-breast-cancer
#3
Nikita Wright, Padmashree C G Rida, Ritu Aneja
Rampant inter-patient and intra-tumor heterogeneity present formidable challenges in the clinical management of triple-negative breast cancer (TNBC) and mandate a "divide-and-conquer" approach wherein deep biomarker profiling drives patient segmentation and development of customized treatments. Genomic and proteomic studies have uncovered several TNBC subtypes each of which represents a distinct disease pathobiology and harbors unique actionable targets that may illuminate sensitivities to specific classes of therapeutics...
June 1, 2017: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/28405497/results-of-a-phase-i-ii-study-of-adjuvant-concurrent-carboplatin-and-accelerated-radiotherapy-for-triple-negative-breast-cancer
#4
Silvia C Formenti, Encouse B Golden, Judith D Goldberg, Xiaochun Li, Jessica Taff, Maria B Fenton-Kerimian, Sharanya Chandrasekhar, Sandra Demaria, Yelena Novik
Purpose: To determine feasibility and explore the clinical efficacy of concurrent radiotherapy and carboplatin as adjuvant treatment of triple negative breast cancer (TNBC). Patients and Methods: Women with Stage I-II TNBC were treated after surgery in a phase I-II prospective trial [NCT01289353]. Weekly carboplatin (AUC = 2.0) was delivered for 6 weeks. Concurrent radiotherapy was delivered in the prone position during weeks 2-4, for a total dose of 40.5 Gy in 15 fractions to the breast, and 46.5 Gy in 17 fractions to the tumor bed...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28382102/bilateral-triple-negative-invasive-breast-cancer-with-a-brca2-mutation-and-glioblastoma-a-case-report-and-literature-review
#5
Ali Raufi, Mohamed Alsharedi, Yousef Khelfa, Maria Tirona
Breast cancer is the second leading cause of death among women in North America. Glioblastoma is the most common primary malignant central nervous system tumor in adults. The majority of hereditary breast cancers are associated with deleterious mutations in the BRCA1 and BRCA2 genes. Although few case reports have described the incidence of glioblastoma in patients previously diagnosed with breast cancer, any association between BRCA2 mutations and glioblastoma has not been demonstrated to date. Herein, we report a woman who is a carrier of a familial BRCA2 mutation, and was previously diagnosed with triple-negative breast cancer (TNBC) and subsequently with a second primary TNBC and glioblastoma...
March 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28277293/prospective-comparison-of-outcome-after-treatment-for-triple-negative-and-non-triple-negative-breast-cancer
#6
D P Joyce, D Murphy, A J Lowery, C Curran, K Barry, C Malone, R McLaughlin, M J Kerin
INTRODUCTION: Triple-negative breast cancers (TNBC) are associated with a poor prognosis owing to an aggressive phenotype. We aimed to carry out a prospective study comparing management strategies and response to therapy in TNBC and non-TNBC patients. METHODS: Data were obtained from a prospectively maintained database of patients treated for breast cancer. RESULTS: A total of 142 TNBC and 142 age-, stage- and NPI-matched non-TNBC patients were treated...
October 27, 2016: Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
https://www.readbyqxmd.com/read/28211614/opportunities-for-improving-triple-negative-breast-cancer-outcomes-results-of-a-population-based-study
#7
Elisabetta Rapiti, Kim Pinaud, Pierre O Chappuis, Valeria Viassolo, Aurélie Ayme, Isabelle Neyroud-Caspar, Massimo Usel, Christine Bouchardy
Triple-negative breast cancer (TNBC) is associated with a poor prognosis. Surgery, radiotherapy, chemotherapy, and referral for genetic counseling are the standard of care. We assessed TNBC prevalence, management, and outcome using data from the population-based Geneva cancer registry. 2591 women had a first invasive stage I-III breast cancer diagnosed between 2003 and 2011. We compared TNBC to other breast cancers (OBC) by χ(2) -test and logistic regression. Kaplan-Meier survival curves, up to 31-12-2014, were compared using log-rank test...
March 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28194329/understanding-breast-cancer-the-long-and-winding-road
#8
REVIEW
Kiven Erique Lukong
BACKGROUND: Despite a remarkable increase in the depth of our understanding and management of breast cancer in the past 50 years, the disease is still a major public health problem worldwide and poses significant challenges. The palpability of breast tumors has facilitated diagnosis and documentation since ancient times. The earliest descriptions of breast cancer date back to around 3500 BCE. For centuries to follow, theories by Hippocrates (460 BCE) and Galen (200 CE), attributing the cause of breast cancer to an "excess of black bile" and treatment options including the use of opium and castor oil, prevailed...
June 2017: BBA Clinical
https://www.readbyqxmd.com/read/28135048/identification-of-recurrent-brca1-mutation-and-its-clinical-relevance-in-chinese-triple-negative-breast-cancer-cohort
#9
Xiaoran Liu, Huiping Li, Bin Shao, Jianmin Wu, Weiyao Kong, Guohong Song, Hanfang Jiang, Jing Wang, Fengling Wan
Triple-negative breast cancer (TNBC) accounts for 15-20% of all newly diagnosed breast cancers, and is enriched for germline mutation of BRCA. In Asian patients diagnosed with breast cancer, 268 deleterious mutations of BRCA1 and 242 of BRCA2 have been identified so far, including a reported BRCA1 frameshift mutation (rs80350973), apparently found only in Asian people, with a low prevalence of 0.3-1.7% in different breast cancer cohorts. Here, we reported the high prevalence (7.2%) of rs80350973 among 125 Chinese patients with TNBC, which implies its mutational predilection for certain breast cancer subtypes...
March 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28108861/in-vivo-magnetic-resonance-imaging-investigating-the-development-of-experimental-brain-metastases-due-to-triple-negative-breast-cancer
#10
Amanda M Hamilton, Paula J Foster
Triple negative breast cancer (TNBC), when associated with poor outcome, is aggressive in nature with a high incidence of brain metastasis and the shortest median overall patient survival after brain metastasis development compared to all other breast cancer subtypes. As therapies that control primary cancer and extracranial metastatic sites improve, the incidence of brain metastases is increasing and the management of patients with breast cancer brain metastases continues to be a significant clinical challenge...
February 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28006062/association-between-benign-breast-disease-in-african-american-and-white-american-women-and-subsequent-triple-negative-breast-cancer
#11
Lisa A Newman, Azadeh Stark, Dhanajay Chitale, Margaret Pepe, Gary Longton, Maria J Worsham, S David Nathanson, Patricia Miller, Jessica M Bensenhaver, Erica Proctor, Monique Swain, Christos Patriotis, Paul F Engstrom
Importance: Compared with white American (WA) women, African American (AA) women have a 2-fold higher incidence of breast cancers that are negative for estrogen receptor, progesterone receptor, and ERBB2 (triple-negative breast cancer [TNBC]). Triple-negative breast cancer, compared with non-TNBC, likely arises from different pathogenetic pathways, and benign breast disease (BBD) predicts future non-TNBC. Objective: To determine whether AA identity remains associated with TNBC for women with a prior diagnosis of BBD...
December 22, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27959276/identification-and-targeting-of-micrornas-modulating-acquired-chemotherapy-resistance-in-triple-negative-breast-cancer-tnbc-a-better-strategy-to-combat-chemoresistance
#12
Samayita Das
Triple negative breast cancer (TNBC) is a heterogeneous form of malignant disease. Due to lack of proper therapeutic target treatment options are restricted and relies primarily on chemotherapeutic modality for treatment of patients. Despite significant early regression of the disease in response to chemotherapy, complete cure is not assured with development of resistant tumors which is difficult to manage clinically. In the last decades, the regulation and contribution of microRNAs in tumorigenesis including breast cancers have been well-documented...
November 2016: Medical Hypotheses
https://www.readbyqxmd.com/read/27882217/multiple-effects-of-xihuang-pill-aqueous-extract-on-the-hs578t-triple-negative-breast-cancer-cell-line
#13
Wenxian Zheng, Shuyan Han, Shantong Jiang, Lina Pang, Xiaohong Li, Xijuan Liu, Minhua Cao, Pingping Li
The management of triple-negative breast cancer (TNBC) is challenging due to the aggressive behavior, lack of therapeutic options and relatively poor prognosis. Xihuang pill (XHP) is a well-known Traditional Chinese Medicine with anticancer activity. The aim of the present study was to investigate whether the aqueous extract of XHP (AEXHP) has anti-proliferative activity against the Hs578T TNBC cell line, and to elucidate its molecular mechanisms of action. First, an MTT assay was used to evaluate the anti-proliferative activity of AEXHP on the Hs578T cell line; furthermore, the cell cycle distribution, mitochondrial membrane potential and apoptotic rate were determined by flow cytometry, and western blot analysis was used to assess the expression of apoptosis and cell cycle regulatory proteins to investigate the mechanisms of action...
November 2016: Biomedical Reports
https://www.readbyqxmd.com/read/27856201/daily-practice-management-of-pt1a-b-pn0-breast-carcinoma-a-prospective-french-odissee-cohort-study
#14
MULTICENTER STUDY
Florence Dalenc, Frédérique Penault-Llorca, Monique Cohen, Gilles Houvenaeghel, Jean-Marc Piat, Philippe Liegeois, Laurent Puyuelo, Jean-Philippe Suchaud, Mohammed Zouai, Magali Lacroix-Triki, Nina Radosevic-Robin, Chahinez Benkanoun, Hanane Attar-Rabia, Marie-Pierre Chauvet, Joseph Gligorov, Yazid Belkacemi
BACKGROUND: Most breast cancer (BC) tumors ≤10 mm have an excellent prognosis. The subgroups with a higher risk for distant recurrence requiring adjuvant systemic therapy are not precisely defined in current international guidelines. PATIENTS AND METHODS: The OBSERVATOIRE DES PETITS CANCERS DU SEIN HER2 +/- (ODISSEE) study was a prospective, multicenter, cohort study that aimed to describe the daily adjuvant management and outcome of 616 patients with unifocal, invasive pT1a-b pN0 nonmetastatic BC who underwent surgery...
April 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27817751/novel-insight-into-triple-negative-breast-cancers-the-emerging-role-of-angiogenesis-and-antiangiogenic-therapy
#15
Cornelia Braicu, Roxana Chiorean, Alexandru Irimie, Sergiu Chira, Ciprian Tomuleasa, Emilian Neagoe, Angelo Paradiso, Patriciu Achimas-Cadariu, Vladimir Lazar, Ioana Berindan-Neagoe
Triple-negative breast cancer (TNBC) is a heterogeneous group of tumours characterised by lack of expression of oestrogen-, progesterone- and human epidermal growth factor receptors. TNBC, which represents approximately 15% of all mammary tumours, has a poor prognosis because of an aggressive behaviour and the lack of specific treatment. Accordingly, TNBC has become a major focus of research into breast cancer and is now classified into several molecular subtypes, each with a different prognosis. Pathological angiogenesis occurs at a late stage in the proliferation of TNBC and is associated with invasion and metastasis; there is an association with metabolic syndrome...
November 7, 2016: Expert Reviews in Molecular Medicine
https://www.readbyqxmd.com/read/27816751/growth-hormone-releasing-hormone-induced-transactivation-of-epidermal-growth-factor-receptor-in-human-triple-negative-breast-cancer-cells
#16
Eva Vacas, Laura Muñoz-Moreno, Pedro L Valenzuela, Juan C Prieto, Andrew V Schally, María J Carmena, Ana M Bajo
Triple-negative breast cancer (TNBC) is a subset of breast cancers which is negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptor-2 (HER2). Chemotherapy is currently the only form of treatment for women with TNBC. Growth hormone-releasing hormone (GHRH) and epidermal growth factor (EGF) are autocrine/paracrine growth factors in breast cancer and a substantial proportion of TNBC expresses receptors for GHRH and EGF. The aim of this study was to evaluate the interrelationship between both these signaling pathways in MDA-MB-468 human TNBC cells...
December 2016: Peptides
https://www.readbyqxmd.com/read/27796714/up-regulation-of-cathepsin-s-expression-by-hsp90-and-5-ht7-receptor-dependent-serotonin-signaling-correlates-with-triple-negativity-of-human-breast-cancer
#17
Jaya Gautam, Young Kyung Bae, Jung-Ae Kim
PURPOSE: Cathepsin S (CTSS) is expressed in a variety of cancers and stimulates tumor progression. However, the regulatory mechanism and role of CTSS in breast cancer progression are poorly understood. The aim of this study was to examine the relationships between CTSS expression and breast cancer grade and stage, and the signaling molecules involved in CTSS expression. METHODS: Immunohistochemical staining was performed in tissue microarray sections of 1451 human invasive breast cancer samples to determine epithelial (E-CTSS) and stromal CTSS (S-CTSS) expression...
October 27, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27770782/triple-negative-breast-cancer-in-north-of-morocco-clinicopathologic-and-prognostic-features
#18
Touria Derkaoui, Joaira Bakkach, Mohamed Mansouri, Ali Loudiyi, Mohamed Fihri, Fatima Zahra Alaoui, Amina Barakat, Bouchra El Yemlahi, Hassan Bihri, Naima Ghailani Nourouti, Mohcine Bennani Mechita
BACKGROUND: Triple Negative Breast Cancer (TNBC) is defined by a lack of estrogen and progesterone receptor gene expression and by the absence of overexpression on HER2. It is associated to a poor prognosis. We propose to analyze the clinicopathologic and prognostic characteristics of this breast cancer subtype in a Mediterranean population originated or resident in the North of Morocco. METHODS: We conducted a retrospective study of 279 patients diagnosed with breast cancer between January 2010 and January 2015...
October 22, 2016: BMC Women's Health
https://www.readbyqxmd.com/read/27765921/triple-negative-breast-cancer-is-there-a-treatment-on-the-horizon
#19
REVIEW
Hui Yao, Guangchun He, Shichao Yan, Chao Chen, Liujiang Song, Thomas J Rosol, Xiyun Deng
Triple-negative breast cancer (TNBC), which accounts for 15-20% of all breast cancers, does not express estrogen receptor (ER) or progesterone receptor (PR) and lacks human epidermal growth factor receptor 2 (HER2) overexpression or amplification. These tumors have a more aggressive phenotype and a poorer prognosis due to the high propensity for metastatic progression and absence of specific targeted treatments. Patients with TNBC do not benefit from hormonal or trastuzumab-based targeted therapies because of the loss of target receptors...
January 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/27721875/histomorphological-factors-predicting-the-response-to-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer
#20
Yoon Yang Jung, Chang Lim Hyun, Min-Sun Jin, In Ae Park, Yul Ri Chung, Bobae Shim, Kyu Ho Lee, Han Suk Ryu
PURPOSE: There is no standard targeted therapy for the treatment of triple-negative breast cancer (TNBC). Therefore, its management heavily depends on adjuvant chemotherapy. Using core needle biopsy, this study evaluated the histological factors of TNBC predicting the response to chemotherapy. METHODS: One hundred forty-three TNBC patients who received single-regimen neoadjuvant chemotherapy (NAC) with the combination of doxorubicin, cyclophosphamide, and docetaxel were enrolled...
September 2016: Journal of Breast Cancer
keyword
keyword
55830
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"